BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Parker Hughes Cancer Center Release: New Drug Effective Against HER2 Positive Breast Cancer In Transgenic Mice


10/19/2005 5:11:02 PM

ROSEVILLE, Minn., Oct. 18 /PRNewswire/ -- Parker Hughes scientists have developed a new technology capable of preventing the development of breast cancer in mice. The results from these research studies will be published in two back-to-back papers in the November issue of the prestigious international medical journal Arzneimittelforschung (Drug Research). The technology was developed through the combined use of chemistry, biology, bioinformatics, pharmacology, and mathematics.

In the studies Parker Hughes scientists found that a novel cytotoxic nucleoside analog, Compound 003 [3'-Azidothymidine 5' - [p-Methoxyphenyl methoxyalaninyl phospate], was well tolerated in both mice and rats without toxicity. Most notably Compound 003 prolonged cancer-free survival in transgenic mice, which otherwise invariably develop HER2 positive metastatic breast cancer, without any significant side effects and at dose levels much lower than those found to be safe in animals.

An estimated 216,000 women will be diagnosed with breast cancer this year. Sadly, roughly 40,000 women will die. Women with HER2 positive breast cancer have a greater risk for recurrence of their breast cancer and an increased risk of mortality.

References: Publication #1

Uckun FM, Vassilev AO, Dibirdik I, Liu XP, Erbeck D, Tibbles HE, Qazi S, Venkatachalam TK. Anti-Cancer Activity Profile of 3'-Azidothymidine 5'-[p- Methoxyphenyl methoxyalaninyl phosphate] (Compound 003), a Novel Nucleoside Analog. Arzneimittelforschung/Drug Research, Accepted, Exp Pub 11/ 2004

Publication #2

Uckun FM, Chen CL, Liu XP, Dibirdik I, Venkatachalam T. In Vitro and In Vivo Pharmacokinetic Features and Metabolism of the Novel Cytotoxic Nucleoside Analog Compound 003, 3'-Azidothymidine 5'-[p-Methoxyphenyl methoxyalaninyl phosphate]. Arzneimittelforschung/Drug Research, Accepted, Exp Pub 11/2004

Parker Hughes

CONTACT: Tom Knisely of Parker Hughes, +1-651-295-2990



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES